Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective
about
Selective Estrogen Receptor ModulatorsAn overview on the treatment of postmenopausal osteoporosisBone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women's health practiceLong-term treatment of osteoporosis: safety and efficacy appraisal of denosumabObservations following discontinuation of long-term denosumab therapy.Periodontal regeneration using strontium-loaded mesoporous bioactive glass scaffolds in osteoporotic ratsClinician's Guide to Prevention and Treatment of OsteoporosisRomosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosisFracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study.Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis.Effect of bisphosphonates on the rapidly growing male murine skeleton.Skeletal and extraskeletal actions of denosumab.Status of drug development for the prevention and treatment of osteoporosis.Osteoporosis therapy: a novel insight from natural homeostatic system in the skeleton.Swedish osteoporosis care.The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost.Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis.Bisphosphonate Withdrawal: Effects on Bone Formation and Bone Resorption in Maturing Male Mice.Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study.Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies.Hip fracture trends in the United States, 2002 to 2015.Severe hypercalcemia following denosumab treatment in a juvenile patient.Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy
P2860
Q26738923-64C07FC2-47B2-4C6A-98F8-CCB69EA86D45Q27013070-C255E8A5-E503-4BCE-8B8C-52A939790950Q28066185-D76EBF96-EAA1-4A87-89DE-5B1CB448D054Q28727655-D3217478-8815-42F1-B0E2-2E4914312233Q33563846-9F1FDD41-B630-4738-A61D-251EAAA545CDQ34035155-795BDDF2-FE2A-480C-88A8-29E50D499A3DQ34250632-7CB43979-CE7C-4AFD-AB52-E26F54734C5DQ35507830-C2792E25-D230-4E9F-9647-D607F2A71607Q35536507-9C5A23C5-BBE0-49C7-99E5-62D9C89235D9Q36233521-5E3C9DB1-B6F3-4CF0-9565-B8448840EBE3Q37648066-0AAD0CCA-33B7-4084-A5BD-564B4B4293AEQ38009712-1C0E9EB8-77BB-48D6-9C8C-EE216894B6AAQ38184588-F510756C-EB60-428B-9BB8-7A338313DD9DQ38257484-280CE453-B3C1-41FF-8D99-E2FFB632CEABQ38563886-D1234390-184D-44F7-B3D9-E13AC4942BFCQ38611601-062E0D75-56CD-476C-AAB8-9334F8B55137Q38788967-E6136258-AA5E-4CD1-BDC0-CDA94A346EF2Q38793382-8A6510D3-E45D-47B1-9B41-CE66E419D7C9Q39124555-141A74B4-6490-4257-B52F-41FB418A1D9EQ39328095-EC382E21-0064-44C3-9FB1-B385089B78BFQ44468289-A0F4AACB-1B84-456A-8282-4A66E0D4507EQ47241208-C49BD674-1A53-4ACA-BE77-61FEF807C2A3Q52937892-098A02D8-DDDF-471F-96AF-004F3CB08840Q52985345-4171F70A-0E1E-47F9-AE64-CCA5A005AE8BQ57147876-D15A6EBF-06E0-4591-88D3-B5B29515C716
P2860
Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Postmenopausal osteoporosis tr ...... d fracture risk--a perspective
@ast
Postmenopausal osteoporosis tr ...... d fracture risk--a perspective
@en
Postmenopausal osteoporosis tr ...... d fracture risk--a perspective
@nl
type
label
Postmenopausal osteoporosis tr ...... d fracture risk--a perspective
@ast
Postmenopausal osteoporosis tr ...... d fracture risk--a perspective
@en
Postmenopausal osteoporosis tr ...... d fracture risk--a perspective
@nl
prefLabel
Postmenopausal osteoporosis tr ...... d fracture risk--a perspective
@ast
Postmenopausal osteoporosis tr ...... d fracture risk--a perspective
@en
Postmenopausal osteoporosis tr ...... d fracture risk--a perspective
@nl
P2093
P2860
P3181
P356
P1476
Postmenopausal osteoporosis tr ...... d fracture risk--a perspective
@en
P2093
Dirk Vanderschueren
Erik F Eriksen
Felicia Cosman
Ian R Reid
Juliet Compston
Paul D Miller
Philip N Sambrook
Serge Ferrari
Steven Boonen
P2860
P304
P3181
P356
10.1002/JBMR.1570
P407
P577
2012-05-01T00:00:00Z